| NCT06100276 | Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) | RECRUITING | PHASE1, PHASE2 | 2024-08-01 | 2031-03-30 | 2026-09-30 |
| NCT06063850 | AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | RECRUITING | PHASE1, PHASE2 | 2024-06-12 | 2031-12 | 2026-11-30 |
| NCT06270316 | Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease | RECRUITING | PHASE1, PHASE2 | 2024-06-05 | 2027-12-01 | 2027-12-01 |
| NCT05243017 | Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-10-07 | 2029-10-07 | 2029-03 |
| NCT04120493 | Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease | RECRUITING | PHASE1, PHASE2 | 2019-09-06 | 2029-12 | 2029-06 |
| NCT02904772 | Alipogene Tiparvovec for the Treatment of LPLD Patients | WITHDRAWN | PHASE2 | 2016-10 | 2020-09 | 2020-06 |
| NCT03300453 | Intracerebral Gene Therapy in Children With Sanfilippo Type B Syndrome | COMPLETED | PHASE1, PHASE2 | 2013-09-17 | 2019-11-27 | 2019-11-27 |